Research Programs Discontinued
0
Drugs Discontinued
0
since passage of the Inflation Reduction Act
News Updates
Incubate’s Investment Tracker measures the impacts of the Inflation Reduction Act’s healthcare provisions on the life sciences ecosystem, with special attention to the impacts of the small molecule penalty.
Date
Disease Area
Drug Type
Announcement Type
Company Size
Search
March 8, 2026
Mahzi Therapeutics
Orphan Drug Designation
treatment of Pitt Hopkins syndrome
Disease Area: Rare Disease
March 8, 2026
OcuNeo Therapeutics Inc.
Orphan Drug Designation
Sioux Falls
1-50 employees
treatment of vernal keratoconjunctivitis
Disease Area: Rare Disease
March 6, 2026
GENFIT
Orphan Drug Designation
treatment of acute-on-chronic liver failure
Disease Area: Rare Disease
March 6, 2026
Aminex Therapeutics, Inc.
Orphan Drug Designation
Kenmore
1-50 employees
prevention of allograft rejection in liver transplantation
Disease Area: Rare Disease
March 5, 2026
Aminex Therapeutics, Inc.
Orphan Drug Designation
Kenmore
1-50 employees
treatment of malignant glioma
Disease Area: Rare Disease
March 5, 2026
Multitude Therapeutics Inc.
Orphan Drug Designation
Shanghai
1-50 employees
treatment of malignant glioma
Disease Area: Rare Disease
March 5, 2026
Multitude Therapeutics Inc.
Orphan Drug Designation
Shanghai
1-50 employees
treatment of soft tissue sarcoma
Disease Area: Rare Disease
March 5, 2026
RNR Biomedical inc
Orphan Drug Designation
Tenafly
1-50 employees
treatment of Behcet disease
Disease Area: Rare Disease
March 2, 2026
Shanghai Allovanta Biotechnology Co., Ltd.
Orphan Drug Designation
Shanghai
1-50 employees
treatment of follicular lymphoma
Disease Area: Rare Disease
March 2, 2026
Takeda Development Center Americas, Inc.
Orphan Drug Designation
Cambridge
1-50 employees
treatment of narcolepsy type 1
Disease Area: Rare Disease